In 2012 SETBP1 was identified as a novel oncogene in aCML; specific somatic mutations of this gene were discovered in patients affected by atypical Chronic Myeloid Leukemia (aCML) and related diseases.
In 2012 Dr. Gambacorti-Passerini discovered SETBP1 as a novel oncogene and identified specific mutations of this gene in patients affected by atypical Chronic Myeloid Leukemia (aCML).